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The sampleswerethen mounted on aluminum stubs and sputter-
coated with gold.
For comparison, tissue-culture cellswithout spirochetes were
similarlyprepared. Also, spirochetesgrownin BSKII alone were
gentlydrawn down on a 0.2 um milliporefilter and the filter was
processedfor scanningelectronmicroscopyas above (figure lA).
In each instance, spirochetes could be seen attached to most
(figure IB),but not all, of the cellsgrownin tissueculture.Higher
magnification revealed that the spirochetes usually appeared as
intertwined pairs at the host cell surface (figure Ie), and they
were easily distinguished from the surface features of cultured
cells that were not inoculated with spirochetes (figure ID). We
did not observethe spirochetesassociated with small round bod-
ies on the cell surface as reported with the spirochete-tick cell
cultures[7].Wehaveestablishedconditionsthat allowthe B burg-
dorferi spirocheteto growand attach to mammalian cellsin vitro.
This is the first step in the design of experiments for studying
the parameters of attachment and the mechanismsof spirochete
pathogenicity in mammalian cells.
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Single-Dose Therapy for Oral Candidiasis with
Fluconazole in HIV-Infected Adults: A Pilot Study
COLLEAGUES-Oral candidiasis isa commonproblemin neoplastic
diseases, after prolonged antibiotic therapy, or in the aged, de-
bilitated patient, but most cases are now seen in human immu-
nodeficiencyvirus (HIV)-infected patients [I, 2]. In this setting,
the infection is especially difficult to treat: topical antifungals
are unpalatable, only partially effective,and relapsesafter treat-
ment are generally observed. Systemic ketoconazole represents
an efficient alternative, but hepatic toxicity [3]and the possibil-
ity of drug interaction with other medications frequently taken
by these patients, like zidovudine, are of concern.
Fluconazole, (Pfizer, Zurich) is a novelbis-triazoleantifungal
agent exhibitingthe followingfavorable pharmacokinetic prop-
erties:(1)goodabsorption after oral administration(85010 bioavail-
This study was approved by the Research Ethics Committee of the
Department of Internal Medicine at the Centre Hospitalier Universitaire
Vaudois, Lausanne, and written informed consent was obtained from all
subjects who received fluconazole.
Fluconazole was supplied by Pfizer, Fluelastrasse 7, 8048 Zurich, Swit-
zerland.
Please address requests for reprints to Dr. M. P. Glauser, Division of
Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011
Lausanne, Switzerland.
ability), (2) long plasma half-life (30 h), (3) low-plasma protein
binding (11 010) with a rapid distribution in tissue fluids such as
saliva,and (4) predominantly renal excretion(60010) [4J.Prelimi-
nary experience in 95 patients with oropharyngeal candidiasis
showed the drug was effectiveand well tolerated when given as
a 50 mg capsule once daily for a median period of 9 d [5]. How-
ever, the above-mentioned pharmacokinetic properties suggest
that a single-dosetreatment could be effective. Wetested this hy-
pothesisin an open, noncomparativestudy in HIV-infected adults
presenting with oral candidiasis.
From I October 1987, all HIV-positive adults presentingat our
institution with oral candidiasis wereproposed a singleoral dose
of 150mg fluconazole as sole treatment. Patients with mouth
symptoms (pain, burning, and dryness) and characteristic signs
(raisedconfluentwhitepatcheson a hyperemic base)were included
if the swab culture of the lesions showed ~1O Candida colonies
after inoculation on a whole Sabouraud agar plate at bedside.
Eligiblepatients took a 150mg fluconazole capsule under di-
rect medical supervision and were seen again on days 4, 7, and
14-21and then once a month (within the framework of an ongo-
ing AIDS cohort study). The culture was repeated on days 7 and
14-21.The clinical response was defined by the total disappear-
ance of signsand symptoms, and the microbiologic response by
the disappearanceof Candida on culture,or a drop of two grades
or more on a four-grade semiquantitative culture scale (table I).
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Table 1. Clinical and microbiological evolution. didiasis. The clinical response persisted in 22 (96070) of 23 pa-
tients on day 7, in 16(73070) of 22 on days 14-21,and in 11 (52070)
Patient (no. of 21 on day 42;2 patients died from other complications of their
previous epi- Day 14-21 Day 42 HIV infection. A microbiologic response was documented in 20
sodes oral Day 0 Day 7 (87070) of 23 patients on day 7, and persisted in 9 (41070) of 22
candidiasis Clinical Clinical on days 14-21 (table I). Among the 10 patients in whom signs
within 6 mo) Culture" Culture" relapse Culture* relapse and symptoms recurred, the free interval after the administra-
1 (2) 4 1 no 2 no tion of fluconazole was 6-33 d (median: 18 d).
2 4 0 yes 3 ND In this observation, the successrate for a single-dosetreatment
3 (6) 3 0 yes 3 ND of oral candidiasis with fluconazole was 100070 at day 4, but signs
4 3 0 no 3 no and symptoms recurred in 10 patients during the study period.
5 (2) 4 4t ND ND ND Seven had one or more episode of oral candidiasis during the
6 4 2 no 2 no previous 6 mo, and six had AIDS. However,all responded again
7 (5) 3 0 no 3 no to a second 150mg dose of fluconazole. The drug was welltoler-
8 3 0 yes 3 ND ated in all patients, and no hepatic, renal, or hematologic side
9 (I) 3 1 no 3 yes effects were observed. Among the 23 patients, 18were enrolled
10 3 0 no 0 no in a prospectivezidovudine postmarketing surveillanceprogram,
11 4 0 no 3 no and fluconazoledid not appear to be associatedwith suchzidovu-
12t 3 0 dine toxicityas granulocytopenia or anemia. As plasma drug levels
13 (7) 2 1 yes 3 ND werenot measured, the possibilityof subclinicalinteractioncould
14t 3 3 no 3 not be excluded.The correlation betweenthe culture and the clin-
15 3 2 no 1 no ical responsewasweakafter day 7: An increasingnumber of Can-
16 (1) 3 0 no 0 yes dida upon semiquantitative cultures wasnot predictiveof a clini-
17 4 0 no 1 no cal relapse.Culture was helpful only for the initial confirmation
18 (3) 3 0 no 2 yes of the clinical diagnosis.
19 (3) 3 0 yes 3 ND Single-dose fluconazole oral therapy for oropharyngeal can-
20 3 0 no 2 no didiasis was easy to administer, effective, and well tolerated in
21 4 1 no I no our limited pilot study. This therapeutic approach might avoid
22 3 0 no 0 yes continuous treatment in patients in whom advancedimmunosup-
23 3 I no 1 no pression induces frequent relapsesand is of special interest when
ketoconazole cannot be used.
NOTE. No patients had clinical relapse on day 4. ND = no J. P. CRAVE, A. CAlor, J. BILLE, M. P. GLAUSER
analysis after first relapse. Division of Infectious Diseases, Department of Internal
* 0 = no growth, I = 1-9 Candida colonies, 2 = 10-19colo- Medicine and Institute of Microbiology, Centre Hospitalier
nies, 3 = ~ 20 colonies, 4 = confluent growth.
t Patient 5 had clinical relapse on day 7. Universitaire Vaudois, Lausanne, Switzerland
t Died during study period.
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